SpaceX Stock Draws Bullish Wall Street Coverage Ahead of Nasdaq-100 Inclusion 
Barclays Downgrades Siemens Energy as Valuation Seen Near Peak 
BHP Faces Port Hedland Strike Threat as Iron Ore Export Risks Grow 
Shell Raises Q2 Upstream Outlook, Flags Qatar Gas Hit as Shares Rise 
Apple Tests China's CXMT Memory Chips as DRAM Maker Gains Global Market Share 
Lockheed Martin, Rheinmetall Plan First ATACMS Missile Production in Germany 
China 618 Smartphone Sales Drop 13% as Higher Prices Hurt Demand, Huawei Gains Market Share 
SK Hynix’s $28 Billion U.S. Share Sale Draws Massive Demand Amid AI Chip Boom 
SK Hynix’s $28B U.S. IPO Draws Strong Demand as AI Chip Boom Fuels Investor Interest 
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
Japan Regional Bank Stocks Drop After Zentoshin Bankruptcy Sparks Credit Risk Concerns 
Zhipu AI Stock Jumps on Report of Custom AI Chip Development Plans 
Bain Capital Exits Kioxia After AI-Fueled Valuation Surge 
Oil and LNG Tankers Turn Back as Strait of Hormuz Security Risks Escalate 
Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion 
Telenor to Buy Controlling Stake in Bahnhof in $630 Million Broadband Deal 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
NEW YORK, May 08, 2018 -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed against Cancer Genetics, Inc. (“Cancer Genetics” or the “Company”) (Nasdaq:CGIX) in the United States District Court for the District of New Jersey on behalf of a class consisting of investors who purchased or otherwise acquired Cancer Genetics securities on the open market from March 23, 2017 through April 2, 2018, inclusive (the “Class Period”).
Investors who have incurred losses in shares of Cancer Genetics, Inc., you may contact the firm at [email protected] or (800) 575-0735 or (212) 545-4774. You may obtain additional information concerning the firm on our website, www.whafh.com.
On April 2, 2018, the Company reported that following the departure of its former CEO, it undertook a “comprehensive and extensive review” of its strategy and organization.
As a result, the Company recorded a bad debt expense of $4.4 million and wrote off $1.8 million of its accounts receivable in the fourth quarter of 2017, largely related to “collection issues” with respect to the accounts receivable recorded subsequent to the Company’s 2015 acquisition of Response Genetics Inc.
The Company further disclosed that it “had a Material Weakness in Internal Controls Over Financial Reporting at December 31, 2017” and that its 2017 annual report would contain a going concern qualification.
On this news, Cancer Genetics’ share price fell $0.55 per share, or 33.3%.
Wolf Haldenstein Adler Freeman & Herz LLP has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country. The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego. The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.
If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735, via e-mail at [email protected], or visit our website at www.whafh.com.
## Follow the firm and learn about newly filed cases on Twitter and Facebook. ##
Contact:
Wolf Haldenstein Adler Freeman & Herz LLP
Kevin Cooper, Esq.
Gregory Stone, Director of Case and Financial Analysis
Email: [email protected], [email protected] or [email protected]
Tel: (800) 575-0735 or (212) 545-4774
Attorney Advertising. Prior results do not guarantee or predict a similar outcome.
